
Waters (WAT) Stock Forecast & Price Target
Waters (WAT) Analyst Ratings
Bulls say
Waters is positioned well in the life science tools industry with its diverse portfolio of analytical instruments, including liquid chromatography, mass spectrometry, and thermal analysis tools. The recent merger with BD's life science and diagnostics business has increased the company's concentration in diagnostics and potential for further consolidation in the industry. The management team's successful track record for turning around and integrating businesses, particularly with the 2015 acquisition of Sigma-Aldrich, adds confidence to their ability to drive growth and efficiency for Waters. This, along with a strong outlook for the drug manufacturing industry and a minimal exposure to academic and government headwinds, make Waters a strong performer in the tools sector.
Bears say
Waters is facing several fundamental challenges that may hinder its growth potential and financial performance. These challenges include a high concentration in diagnostics and life science tools, potential share loss in key product categories, sustainability concerns such as environmental impact and human capital management, and a limited pricing upside opportunity due to entrenched customers and a two-player market. The 2026 merger with BD may provide near-term benefits, but the company will need to focus on successful integration and potential industry consolidation in order to drive future growth. Ultimately, Waters' long-term outlook for EBIT expansion and EPS growth may be hindered by these fundamental challenges and changing materiality factors in the industry.
This aggregate rating is based on analysts' research of Waters and is not a guaranteed prediction by Public.com or investment advice.
Waters (WAT) Analyst Forecast & Price Prediction
Start investing in Waters (WAT)
Order type
Buy in
Order amount
Est. shares
0 shares